UPMC Physicians and Researchers Present at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2018 The 2018 ASCO Annual Meeting will be held June 1-5, 2018 in Chicago, IL. UPMC physicians and researchers will be represented with presentations, poster sessions and abstracts. Some of the presentations and abstracts include: 

Friday, June 1

4:30 PM - 6:00 PM
Location: S100bc
Clinical Science Symposium
Integrating Immunotherapy Into Standard of Care for Head and Neck Cancer
Track(s): Head and Neck Cancer
Chair(s): Renata Ferrarotto, MD , The University of
Texas MD Anderson Cancer Center Thomas James
Galloway, MD , Fox Chase Cancer Center
CE/MOC Credit: 1.5
Abstract 6010, Safety evaluation of nivolumab (Nivo) concomitant with cetuximabradiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.
4:54 PM - 5:06 PM
Robert L. Ferris, MD, PhD, FACS - First Author
University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute 


Saturday, June 2
8:00 AM - 11:30 AM
Location: Hall A
Poster Session
Genitourinary (Nonprostate) Cancer
Track(s): Genitourinary (Nonprostate) Cancer
CE/MOC Credit: 0
Abstract 4573, Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study.
Poster Board: #399
Leonard Joseph Appleman, MD, PhD - First Author
University of Pittsburgh

1:15 PM - 4:45 PM
Location: Hall A
Poster Session
Health Services Research, Clinical Informatics, and Quality of Care
Track(s): Health Services Research, Clinical Informatics, and Quality of Care
CE/MOC Credit: 0
Abstract 6568, Overall survival based on oncologist density in the United States: Do we need to redefine underserved areas for oncologic care?
Poster Board: #394
Kathan Mehta, MBBS, MPH - First Author
University of Pittsburgh Medical Center

3:00 PM - 4:15 PM
Location: S100a
Award Lecture
Allen S. Lichter Visionary Leader Award and Lecture
Track(s): Special Sessions
CE/MOC Credit: 1.25, Serendipity and Purpose
3:05 PM - 4:15 PM
Nancy E. Davidson, MD, FASCO - Award Lecturer
University of Pittsburgh Cancer Institute

Sunday, June 3

8:00 AM - 11:00 AM
Location: E451
Oral Abstract Session
Head and Neck Cancer
Track(s): Head and Neck Cancer
Chair(s): Jessica Ruth Bauman, MD , Fox Chase
Cancer Center Charu Aggarwal, MD, MPH , Abramson
Cancer Center
CE/MOC Credit: 3
Abstract 6003, Treatment deintensification to surgery only for stage I human papillomavirus-associated oropharyngeal cancer.
9:00 AM - 9:12 AM
John David Cramer, M.D. - First Author
University of Pittsburgh School of Medicine

8:00 AM - 11:30 AM
Location: Hall A
Poster Discussion Session
Gastrointestinal (Noncolorectal) Cancer
Track(s): Gastrointestinal (Noncolorectal) Cancer
Chair(s): Sunil Sharma, MD, FACP, MBA ,
Translational Genomics Research Institute (TGen)
Vaibhav Sahai, MBBS, MS , University of Michigan
Comprehensive Cancer Center
CE/MOC Credit: 0
Abstract 4015, Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer.
Poster Board: #204
Nathan Bahary, MD, PhD - First Author
University of Pittsburgh Medical Center Cancer Pavilion 

8:00 AM - 11:30 AM
Location: Hall A
Poster Session
Gastrointestinal (Colorectal) Cancer
Track(s): Gastrointestinal (Colorectal) Cancer
Chair(s):
CE/MOC Credit: 0
Abstract TPS3615, Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.
Poster Board: #108a
James J. Lee, MD, PhD - First Author
NSABP Foundation, and The University of Pittsburgh

Monday, June 4

1:15 PM - 4:45 PM
Location: Hall A
Poster Session
Tumor Biology
Track(s): Tumor Biology
CE/MOC Credit: 0
Abstract 12046, Use of cell-free DNA for management of breast and lung cancer by academic and community providers.
Poster Board: #159
Roby Antony Thomas, MD - First Author
University of Pittsburgh Medical Center

1:15 PM - 4:45 PM
Location: Hall A
Poster Session
Melanoma/Skin Cancers
Track(s): Melanoma/Skin Cancers
CE/MOC Credit: 0
Abstract 9586, Surveillance for melanoma (MEL): Results of a database study of stage I-III MEL.
Poster Board: #413
Corey Rearick - First Author
University of Pittsburgh School of Medicine

4:45 PM - 6:00 PM
Location: S504
Education Session
Challenges Facing Family Caregivers and Emerging Novel Interventions
Track(s): Pediatric Oncology; Patient and Survivor Care
Chair(s): Sung Won Choi, MD, MS , University of Michigan
CE/MOC Credit: 1.25
Psychosocial Support and Coping Skills in Family Caregiving
5:00 PM - 5:15 PM
Robert Noll, PhD - Speaker
University of Pittsburgh

UPMC Affiliated Abstracts:

1. Surveillance for melanoma (MEL): Results of a database study of stage I-III MEL. Corey Rearick, Fei Ding, Yan Lin, Amy Rose, Cindy Sander, Michael Davis, Panayiotis V Benos, Hussein Abdul-Hassan Tawbi, Ahmad A. Tarhini, John M. Kirkwood, Diwakar Davar. Abstract #: 9586. Presented Monday, June 4, 2018.

2. Validation of a prognostic 53-immune-gene panel in stage II/III melanoma: Margaret Borgardus, Robyn Denise Gartrell, Douglas Kanter Marks, Camden L Esancy, Sarabjot Pabla, Marc S. Ernstoff, John M. Kirkwood, Rui R. Chang, Bret Taback, Sandra J. Lee, John Krolewski, Carl Morrison, Yvonne M. Saenger. Abstract #: 9576. Presented Monday, June 4, 2018. 

3. A phase 2, multicenter study to assess the efficacy and safety of autologous tumor-infiltrating lymphocytes (LN-144) for the treatment of patients with metastatic melanoma: Amod Sarnaik, Brendan D. Curti, Diwakar Davar, John M. Kirkwood, Omid Hamid, Jose Lutzky, Melissa Wilson, Harriet M. Kluger, Eric D. Whitman, Giao Q. Phan, Sajeve Samuel Thomas, Karl D. Lewis, Hendrik-Tobias Arkenau, Jason Alan Chesney, Bente Larsen, Igor Gorbatchevsky, Sam Suzuki, Nancy Louise Samberg, Maria Fardis. Abstract #: TPS9595. Presented Monday, June 4, 2018.

4. Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial: Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James M. G. Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Mark Haydon, Caroline Robert, Dirk Schadendorf, Paola Aimone, Bijoyesh Mookerjee, Catarina D. Campbell, James Garrett, Jan C. Brase, Richard Kefford, John M. Kirkwood, Georgina V. Long. Abstract #: 9574. Presented Monday, June 4, 2018.

5. Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL): Ryan Campbell Massa, Mark Sparrow, Huang Lin, Yan Lin, David J. Mauro, Art M. Krieg, Heather Kelley, Amy Rose, Yana G. Najjar, John M. Kirkwood, Diwakar Davar. Abstract #: e21507. 

6. Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma: Dirk Schadendorf, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Haydon, Laurent Mortier, Caroline Robert, Jacob Schachter, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, Reinhard Dummer, John M. Kirkwood, Georgina V. Long. Presented Monday, June 4, 2018.

7. A phase 2 study of intratumoral pIL-12 plus electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma progressing on either pembrolizumab or nivolumab treatment (PISCES): Robert Hans Ingemar Andtbacka, Tom Van Hagen, Phillip Parente, Victoria Atkinson, Igor Puzanov, Gregory A. Daniels, Sajeve Samuel Thomas, Anne Poh Long, Andrew Mark Haydon, Arkadiusz Z. Dudek, Sharron Erna Gargosky, Chris Twitty, John M. Kirkwood. Abstract #214305. 

8. Novel cyopreserved tumor infiltrating lymphocytes (LN-144) administered to patients with metastatic melanoma demonstrates efficacy and tolerability in a multicenter Phase 2 clinical trial: Sarnaik A, Curti B, Kirkwood JM, Hamid O, Lutzky J, Kluger H, Whitman E, Phan G. Sajeve T, Lewis K, Fardis M, Gorbatchevsky I, Suzuki S, Samberg N.  Late breaking abstract.